Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Ipilimumab 96 pembrolizumab 82 Nivolumab 79 aldesleukin 51 Cyclophosphamide 49 Interleukin-2 38 fludarabine phosphate 31 Vemurafenib 31 Dacarbazine 31 dabrafenib 29 trametinib 28 Temozolomide 26 fludarabine 25 CTLA-4 Antigen 18 Bevacizumab 18 Radiosurgery 15 Paclitaxel 15 Carboplatin 14 encorafenib 13 binimetinib 13 Introns 13 talimogene laherparepvec 12 Interferon alpha-2 12 Radiotherapy 11 spartalizumab 10 cobimetinib 10 atezolizumab 10 sargramostim 9 peginterferon alfa-2b 9 montanide ISA 51 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × Tissue Array Analysis × Clear all

NCT02236546 2017-04-13

FDG-PET in Advanced Melanoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated

3 enrolled 4 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡